Targeted therapy in metastatic renal cell carcinoma

Annals of Oncology

Volumn 18, Issue SUPPL. 9, 2007, Pages

  De Mulder, P H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; CYTOKINE; INTERLEUKIN 2; MEDROXYPROGESTERONE; MESSENGER RNA; PLACEBO; PROSTAGLANDIN SYNTHASE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; ANTINEOPLASTIC AGENT; INTERFERON; VASCULOTROPIN A;

ACNE; ANEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG CHOICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMMUNE RESPONSE; KIDNEY CARCINOMA; LEUKOPENIA; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RASH; SIDE EFFECT; SKIN EXFOLIATION; SKIN MANIFESTATION; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; THYROIDITIS; THYROTROPIN BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; DRUG ANTAGONISM; KIDNEY TUMOR; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; HUMANS; INTERFERONS; KIDNEY NEOPLASMS; NEPHRECTOMY; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36048934301     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm303     Document Type: Conference Paper

References (33)

1. Cohen H, McGovern F. Renal Cell carcinoma. N Engl J Med 2005; 353: 3477-3490.
2. www.seer.cancer.gov. 2004.
3. Flanigan RC, Mickisch G, Sylvester R et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis. J Urol 2004; 171: 1071-1076.
4. Kavolius JP, Mastorakos DP, Pavlovich C et al. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998; 16: 2261-2266.
5. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408-417.
6. Stadler WM, Huo D, George C et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 2003; 170: 1141-1145.
7. Coppinn C, Porzsolt F, Awa A et al. Cochrane Database Syst Rev 2005; CD001425.
8. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540.
9. Fossa S, Jones M, Johnson P et al. Interferon-alpha and survival in renal cell cancer. Br J Urol 1995; 76: 286-290.
10. Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22: 454-463.
11. Negrier S, Perol D, Ravaud A et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. J Clin Oncol 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 4511.
12. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11: 3714-3721.
13. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 2003; 9: 802-811.
14. Rini BI, Weinberg V, Dunlap S et al. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 2006; 106: 566-575.
15. Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 1997-2005.
16. Gnarra JR, Zhou S, Merrill MJ et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 1996; 93: 10589-10594.
17. Turner KJ, Moore JW, Jones A et al. Expression of hypoxia-inducible factors in human renal cancer: Relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002; 62: 2957-2961.
18. Wiesener MS, Munchenhagen PM, Berger I et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001; 61: 5215-5222.
19. Grabmaier KA, de Weijert MC, Verhaegh GW et al. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 2004; 22: 5624-5631.
20. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850.
21. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
22. Anonymous. Bevacizumab shows positive outcomes in patients with advanced kidney cancer. 12 Decemeber 2006. Roche Press Release (available online at http://www.docguide.com/news/content.nsf/news/
23. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
24. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524.
25. Motzer RJ, Hutson TE, Pharm D et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
26. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patents with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512.
27. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
28. Raymond E, Alexandre J, Faivre S et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22: 2336-2347.
29. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-918.
30. Smith JW, Ko YJ, Dutcher J et al. Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-α to patients with advanced renal cell carcinoma. J Clin Oncol 2004; 22(14S): 4513.
31. Hudes G, Carducci M, Tomczak P et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006; 24: 2s (Abstract LBA4).
32. Desai J, Yassa L, Marqusee E et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 145: 660-664.
33. Rini BI, George DJ, Michaelson MD et al. Phase II study of Sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (MRCC). Ann Oncol 2006; 17 (supplement 9): Abstract 4380.